Last updated on October 2018

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

Brief description of study

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Clinical Study Identifier: NCT02861534

Contact Investigators or Research Sites near you

Start Over

Georgina Arnold

Merck Sharp & Dohme (Asia) Ltd.
Hong Kong, Hong Kong
  Connect »